abstract |
Novel essential fatty acid based drugs comprising a substantial proportion of docosahexaenoic acid (DHA) in the class of fatty acids esterified in position sn-2 of phosphatidylcholines (PCDHAs) acetylated in position sn-1, or lysophosphatidylcholines (lyso-PCDHAs), or DHA-triglycerides esterified in position sn-2 and acetylated in positions sn-1 and sn-3. Said drugs are useful for treating cardiovascular diseases, including atheromatous disease, and essential fatty acid deficiency, particularly in the brain. |